Valerie Bauman Profile picture
Investigative Reporter @Newsweek. Prior: @BLaw @AP @Newsday. Send tips to v.bauman@newsweek.com. Author of INCONCEIVABLE, out April 16, 2024 via @UnionSqandCo.
Sep 14, 2022 14 tweets 6 min read
.@tacomacc For years I have been trying to remember the name of this wonderful English professor who reignited my love of learning and writing over two decades ago. Can you help? (thread on #education #teaching) Before @tacomacc I went to an expensive Catholic high school in Tacoma that will remain unnamed (cough, cough @BellarminePrep) where I had a horrible experience. I struggled with math & when one lesson was proving especially difficult, I sought extra help.
Sep 13, 2022 9 tweets 2 min read
I GOT A BOOK DEAL! THIS IS NOT A DRILL! (Thread) Image I keep thinking, in this moment, about how eager I was to read & write from a young age. I traced my mother's handwriting in her journals with my chubby index finger before I could read, captivated by the idea of putting thoughts to page.
Aug 19, 2020 6 tweets 3 min read
A document exclusively obtained by @BLaw reveals how @purduepharma bankruptcy dollars would be split among states and local governments. w/ @awolf86 news.bloomberglaw.com/pharma-and-lif… The "abatement plan term sheet" would allow governments to spend money on everything from Narcan, housing and hiring social workers to adding cops in an effort to address the nation's opioid epidemic.
It is not without critics.
Jun 19, 2020 12 tweets 3 min read
It’s no longer just one company seeking to be the first to bring a generic to market-a status that provides 180 days of exclusivity. Instead, multiple companies are sharing first-filer status. So why could more competition be bad for consumers? (thread) news.bloomberglaw.com/pharma-and-lif… In 2019, 14 brand-name drugs had multiple generic first-filers, up from seven in 2013 and zero in 2004, according to Food and Drug Administration data compiled by DrugPatentWatch.com for Bloomberg Law. h/t @thinkbiotech
Feb 10, 2020 9 tweets 4 min read
State & federal enforcers often tout multi-million dollar settlements against pharma companies that pay generic companies to keep a cheaper version of a drug off the market. But do those settlements really discourage anticompetitive behavior? (Thread) news.bloomberglaw.com/health-law-and… A @BLaw analysis breaks down pharma pay-for-delay settlements with state and federal enforcers since the 2013 #SCOTUS decision in FTC v. Actavis, which held these kinds of deals between brand and generics can be illegal.